1. High Level of CD4+CD25+CD127- Treg Cells in Donor Graft is Associated with a Low Risk of aGVHD after allo-HSCT for Children with Hematologic Malignancies
- Author
-
Luo Chengjuan, Luo Changying, Zhu Hua, Xu Kangli, Chen Jing, Zhang Fang, and Wang Jianmin
- Subjects
business.industry ,medicine.medical_treatment ,Incidence (epidemiology) ,hemic and immune systems ,chemical and pharmacologic phenomena ,Retrospective cohort study ,Hematopoietic stem cell transplantation ,Omics ,Treg cell ,surgical procedures, operative ,immune system diseases ,hemic and lymphatic diseases ,Immunology ,Medicine ,Biomarker (medicine) ,IL-2 receptor ,business ,Interleukin-7 receptor - Abstract
Acute Graft-Versus-Host Disease (aGVHD) is the major problem for patient undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). Previous study showed the significant role of CD4+CD25+ Treg cells in inhibiting aGVHD. This retrospective study of 50 children with hematological malignancies undergoing allo-HSCT investigated the influence of donor CD4+CD25+CD127- Treg cells on aGVHD. The proportion of Treg cells in graft is significantly higher in patient with grade 0-I aGVHD than in patients with grade II-IV aGVHD (3.08 ± 0.72% vs. 2.52 ± 0.86%, P=0.016). There was no significant difference on Treg cells proportion in graft between relapsed and non relapsed patients (3.20 ± 0.80% vs. 2.80 ± 0.81% P=0.549). CD4+CD25+CD127- Treg cells in donor graft can reduce the incidence of aGVHD after children received allo-HSCT without increasing the risk of relapse. Graft CD4+CD25+CD127- Treg cells level is a valuable biomarker to predict aGVHD.
- Published
- 2013